Plasminogen activator inhibitor (PAI-1) gene polymorphism (4G/5G) and hepatocellular carcinoma in Egyptian patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2522-8307
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Plasminogen activator inhibitor (PAI-1) gene polymorphism (4G/5G) and hepatocellular carcinoma in Egyptian patients ; volume:43 ; number:1 ; day:10 ; month:12 ; year:2019 ; pages:1-6 ; date:12.2019
Bulletin of the National Research Centre / al- Markaz al-Qaumī li-'l-Buḥūṭ; 43, Heft 1 (10.12.2019), 1-6, 12.2019
- Creator
-
Nemr, Nader
Mandour, Mohamed
Badran, Dahlia
Kishk, Rania
Attia, Fawzy
Hashish, Abdullah
Gaber, Ahmed
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s42269-019-0226-3
- URN
-
urn:nbn:de:101:1-2020040500313567977730
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nemr, Nader
- Mandour, Mohamed
- Badran, Dahlia
- Kishk, Rania
- Attia, Fawzy
- Hashish, Abdullah
- Gaber, Ahmed
- SpringerLink (Online service)
Other Objects (12)
Der 4G/5G-PAI-1-Polymorphismus beim primären Mammakarzinom
P2.03 The Plasminogen Activator Inhibitor-1 (4G/5G) Polymorphism Affects Central Arterial Blood Pressure in Women
Die Bedeutung des 4G/5G-PAI-1-Promotorpolymorphismus beim Ovarialkarzinom
Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis
Systematic review and meta-analysis of association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss: an update
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
Role of plasminogen activator inhibitor-2 (PAI-2) in acute and chronic kidney disease
Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
Der 4G/5G-PAI-1-Polymorphismus beim primären Mammakarzinom
P2.03 The Plasminogen Activator Inhibitor-1 (4G/5G) Polymorphism Affects Central Arterial Blood Pressure in Women
Die Bedeutung des 4G/5G-PAI-1-Promotorpolymorphismus beim Ovarialkarzinom
Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis
Systematic review and meta-analysis of association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss: an update
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
Role of plasminogen activator inhibitor-2 (PAI-2) in acute and chronic kidney disease
Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
Der 4G/5G-PAI-1-Polymorphismus beim primären Mammakarzinom
P2.03 The Plasminogen Activator Inhibitor-1 (4G/5G) Polymorphism Affects Central Arterial Blood Pressure in Women
Die Bedeutung des 4G/5G-PAI-1-Promotorpolymorphismus beim Ovarialkarzinom
Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis
Systematic review and meta-analysis of association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss: an update
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin : characterization of different PAI-1 mutants
Clinical impact of the PAI-1 4G/5G polymorphism in Chinese patients with venous thromboembolism
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
Role of plasminogen activator inhibitor-2 (PAI-2) in acute and chronic kidney disease